Director/PDMR Shareholding-Re

RNS Number : 3848D

Fulcrum Pharma PLC

12 September 2008

 

 CORRECTION- THIS RNS REPLACES THE EARLIER RNS NUMBER 3274D. THE % HOLDINGS IN THE 4TH COLUMN OF 3274D WERE INCORRECT AND ARE REPLACED AS FOLLOWS:

Fulcrum Pharma Plc ('Fulcrum' or the 'Company')

Director shareholding

Fulcrum (AIM: FUL), the drug development and regulatory services company, announces that it was notified on 11 September 2008 that, on 10 September, certain directors, including Frank Armstrong, the Company's new Chief Executive, and Grahame Cook, the recently appointed Chairman-designate, purchased ordinary shares in the Company at a price of 3.6p each as follows:

Director	Number of shares  acquired	Number of shares held  in Company after  acquisition	% of voting rights held following allocation
Dr Frank Armstrong	600,000	600,000	0.34%
Grahame Cook	600,000	600,000	0.34%
Geoffrey Smith	500,000	4,482,744	2.52%

Professor Sir Charles George, Chairman, said 'I am delighted to see that our key directors, including our new chief executive and chairman-designate, have expressed their confidence in the Company's business and prospects by investing in the Company.  I look forward to reporting on our progress in November when we expect to announce our results for the year to 31 August 2008'

For further information, please contact:

Fulcrum Pharma plc
Geoffrey Smith, Finance Director	Tel: [phone]
Seymour Pierce
Jonathan Wright	Tel: [phone]

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that provides global expertise to achieve drug development and regulatory approval milestones. Fulcrum Pharma offers immediate access to a highly credible, integrated development team that provides strategic and operational leadership required to ensure that new drugs move smoothly from discovery research to product approval.

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.

 

END

 

 

RDSBLGDCCBBGGID